Skip to content Skip to sidebar Skip to footer

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

admin 2 February 2023 0Comments

Exscientia plc (Nasdaq: EXAI) today announced that EXS4318 (‘4318) a compound precision designed by Exscientia and in-licensed by Bristol Myers Squibb

0Likes

Exscientia Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318

Leave a comment Cancel reply

You May Also Like

Celgene Pays Exscientia $25 Million up Front for 3-Year AI Research Deal

BMS’ ‘CAR-T in a pill’ multiple myeloma drug has strong early showing at ASCO

Unlock the Future of Pharma: Empower Your Journey with Medicalgogo's AI-Powered Solutions

Newsletter Signup

Quick Links

Space

Contact Us